All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
UNION therapeutics A/S (UNION) has been selected by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge to trial UNI91103 as a prophylactic treatment of COVID-19 in kidney patients, a vulnerable and high-risk patient population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GBS-NN
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $57.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 15, 2020
Details:
Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: UNI91103
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Niclosamide based nasal spray (UNI91103) will first be investigated in high risk patients to test its ability to prevent infection with COVID-19 and to reduce the severity of the disease for those already infected.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
